All News
The Interview (11.7.2025)
I've done thousands of interviews; mostly for medical school admissions or medical and research employment. They’re all the same. I'm looking for the “right one” and the interviewee is somewhere between apprehension, uncertainty and hope. From all this experience I’ve developed my own perspective on interviews and interviewing that has been amended in the digital/virtual era.
Read Article
Ianalumab Shows Phase 3 Success in Sjögren’s: Is It Clinically Meaningful?
On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.
Read Article
Deucravacitinib and Renal Function: Insights from the PAISLEY Trial
In the phase 2 PAISLEY trial, deucravacitinib met its primary and secondary endpoints, demonstrating efficacy across multiple clinical and patient-reported outcomes. However, the impact on renal function has remained unclear. An abstract presented at ACR provides new insights.
Read Article
900,000 vs 9
It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed.
It takes less than nine minutes to make your patient feel seen, understood and reassured.
If you skip the 9 minutes, you wasted the https://t.co/o7BaWjS4HB
Dr. John Cush RheumNow ( View Tweet)
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA
At #ACR25, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in https://t.co/49J2X48i4E
Dr. John Cush RheumNow ( View Tweet)
IL-23 Blockade Goes Oral
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ
Dr. John Cush RheumNow ( View Tweet)
Stopping therapy in GCA
At #ACR25 we saw the SELECT-GCA extension data presented in the first plenary session, looking at the second year after the 52 week original study, comparing upadacitinib versus placebo in GCA. In this second year, patients in remission on upadacitinib https://t.co/GaYNWr3Sjq
Dr. John Cush RheumNow ( View Tweet)
Weight Loss as a Therapeutic Goal in PsA
PsA is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At #ACR25, 3 compelling studies spanning pharmacologic, lifestyle, and longitudinal https://t.co/Q6IFGn5zCI
Dr. John Cush RheumNow ( View Tweet)
IgG4: Rare, but new treatments on the horizon
IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.
https://t.co/v07Kp5tQXg https://t.co/rIvOF0mrM1
Links:
Dr. John Cush RheumNow ( View Tweet)
Do Patients with Rheumatic Diseases 'Weather' the Storm?
Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25.
https://t.co/rY3T6tWsgu https://t.co/vdgT2DB5lH
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib: revisiting safety data in RA and GCA
For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, https://t.co/6Wes2npkFd
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at #ACR25, Here are several of the best abstracts from Day 3, as chosen https://t.co/fOgXSiIWzC
Dr. John Cush RheumNow ( View Tweet)
Replay of RheumNow Live 2025 - Rheumatoid Arthritis https://t.co/TMC0A11Eil
Links:
Dr. John Cush RheumNow ( View Tweet)
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention
At #ACR25, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological https://t.co/OIgh8JQsFa
Dr. John Cush RheumNow ( View Tweet)
A Halloween ACR Guidance (10.31.25)
Dr. Jack Cush recaps #ACR25 with suggestions on how to best learn ACR25 content from RheumNow and our Videos and podcasts.
https://t.co/ik5n4jA3LK https://t.co/lr65m8kRxx
Links:
Dr. John Cush RheumNow ( View Tweet)
The Great Debate – Who Really Won? #ACR25
https://t.co/bh0wxXpVXa https://t.co/Wr8eeW1KsQ
Dr. John Cush RheumNow ( View Tweet)
The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE
Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg
Dr. John Cush RheumNow ( View Tweet)
Belimumab Before or After Immunosuppressant
Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25
https://t.co/BVFhDDfTvW https://t.co/F9ZvGXIqVn
Dr. John Cush RheumNow ( View Tweet)
Using AI and LLMs in Qualitative Data
Dr. Bella Mehta discusses abstract 0794 (Using AI to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models) presented at #ACR25
https://t.co/HFBuNxdZOF https://t.co/gKAXURq8xR
Dr. John Cush RheumNow ( View Tweet)
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?
Despite major advances in RA management, some patients develop difficult-to-treat RA (D2TRA), characterized by ongoing inflammation and impairment despite multiple therapies. While understanding of the https://t.co/FcF0V82KdT
Dr. John Cush RheumNow ( View Tweet)
